Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREZCOBIX vs AVASTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PREZCOBIX is a fixed-dose combination of darunavir, a HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor. Darunavir selectively inhibits the cleavage of HIV-encoded Gag-Pol polyproteins in infected cells, preventing the formation of mature infectious virions. Cobicistat increases systemic exposure of darunavir by inhibiting CYP3A-mediated metabolism.
Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Treatment of HIV-1 infection in combination with other antiretroviral agents in adults and pediatric patients weighing at least 40 kg
Metastatic colorectal cancer (first- or second-line in combination with intravenous 5-fluorouracil-based chemotherapy),Non-small cell lung cancer (first-line in combination with carboplatin and paclitaxel for unresectable, locally advanced, recurrent or metastatic non-squamous disease),Glioblastoma (single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (in combination with interferon alfa),Ovarian epithelial, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel and carboplatin or pegylated liposomal doxorubicin for platinum-sensitive recurrent disease; as a single agent for platinum-resistant recurrent disease),Cervical cancer (in combination with paclitaxel and cisplatin or topotecan for persistent, recurrent, or metastatic disease),Off-label uses: age-related macular degeneration (intravitreal), hereditary hemorrhagic telangiectasia, ovarian cancer (first-line maintenance), breast cancer (not FDA approved)
Darunavir 800 mg (as two 400 mg tablets) plus cobicistat 150 mg (as one 150 mg tablet) orally once daily with food.
5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).
Darunavir: terminal half-life of approximately 15 hours when coadministered with cobicistat, supporting once-daily dosing. Cobicistat: terminal half-life of approximately 3-4 hours, but its inhibitory effect on CYP3A4 persists for 24 hours.
Terminal half-life approximately 20 days (range 11–50 days) in patients; supports dosing every 2–3 weeks
Darunavir is primarily metabolized by CYP3A. Cobicistat is a CYP3A inhibitor and is metabolized by CYP3A and to a minor extent by CYP2D6.
Bevacizumab is primarily metabolized via proteolytic degradation into small peptides and amino acids. No specific metabolic enzymes are involved; it is not metabolized by cytochrome P450 enzymes.
Darunavir: approximately 79.5% in feces (41% as unchanged drug) and 13.9% in urine (7.7% as unchanged drug). Cobicistat: 86% in feces and 8.2% in urine.
Primarily via reticuloendothelial system and proteolytic catabolism; negligible renal excretion (<1% unchanged in urine)
Darunavir: approximately 95% bound to plasma proteins (primarily alpha-1-acid glycoprotein). Cobicistat: 97-98% bound to plasma proteins.
Bound primarily to albumin and other plasma proteins; approximately 95–100% bound (saturable binding to Fc Rn may occur)
Darunavir: apparent Vd of 0.54 L/kg (based on a 70 kg adult, approximately 38 L), indicating distribution into total body water. Cobicistat: apparent Vd of 0.42 L/kg (approximately 29 L).
Vd approximately 2.9–3.7 L (not weight-normalized; small Vd consistent with large monoclonal antibody confined mainly to plasma and interstitial space)
Darunavir: absolute bioavailability is approximately 37% without a boosting agent; when coadministered with cobicistat, bioavailability is enhanced due to inhibition of CYP3A4-mediated first-pass metabolism, but the exact boosted bioavailability is not separately reported. Cobicistat: absolute bioavailability is not determined; it is used as a pharmacokinetic enhancer.
Only available as intravenous infusion; bioavailability 100% by IV route; not administered subcutaneously or orally (no bioavailability data for other routes)
No dose adjustment required in renal impairment including end-stage renal disease on hemodialysis. Cobicistat may decrease estimated creatinine clearance due to tubular secretion inhibition, but actual renal function is preserved.
No dose adjustment is recommended for patients with renal impairment; however, be cautious in severe renal impairment (GFR <30 m L/min) due to limited data.
Child-Pugh A: No adjustment. Child-Pugh B or C: Contraindicated (darunavir metabolism may be impaired, no data for safety/efficacy).
No specific dose adjustment guidelines exist for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment.
Approved for patients weighing ≥40 kg: Darunavir 800 mg plus cobicistat 150 mg orally once daily with food. For <40 kg, alternative formulations (e.g., darunavir boosted with ritonavir) should be used.
Safety and efficacy in pediatric patients have not been established; no standard dosing guidelines available.
No specific dose adjustment. Use with caution due to higher risk of comorbidities, polypharmacy, and potential renal/hepatic impairment; monitor renal function and drug interactions closely.
No specific dose adjustment is required for elderly patients; however, monitor for increased incidence of arterial thromboembolic events, hypertension, and proteinuria as seen in clinical trials.
No FDA boxed warnings reported.
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE. Gastrointestinal perforations occur in up to 2.4% of patients. Discontinue for perforations, tracheoesophageal fistula, or wound dehiscence. Severe or fatal hemorrhage, including hemoptysis and gastrointestinal bleeding, has occurred; monitor for bleeding.
Hepatotoxicity: Drug-induced hepatitis has been reported; monitor liver function before and during therapy.,Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have occurred; discontinue if severe rash or symptoms develop.,Risk of QT prolongation: Use with caution in patients with pre-existing conduction abnormalities or on other QT-prolonging drugs.,Sulfonamide allergy: Darunavir contains a sulfonamide moiety; use with caution in patients with known sulfonamide allergy.,Co-administration with certain drugs: Do not use with drugs highly dependent on CYP3A for clearance or that strongly induce CYP3A (e.g., rifampin).,Diabetes mellitus/hemophilia: May exacerbate existing conditions; monitor accordingly.
Gastrointestinal perforations and fistulae (including tracheoesophageal),Surgery and wound healing complications: do not administer within 28 days of major surgery or until wound is fully healed,Hemorrhage: severe or fatal pulmonary hemorrhage (particularly in squamous NSCLC), gastrointestinal bleeding, and cerebral hemorrhage,Non-gastrointestinal fistula formation (including bronchopleural, biliary, and vaginal),Arterial thromboembolic events (e.g., stroke, myocardial infarction): risk increased in patients ≥65 years of age,Hypertension: monitor blood pressure; may require antihypertensive therapy,Reversible posterior leukoencephalopathy syndrome (RPLS),Proteinuria: monitor urine protein; discontinue if nephrotic syndrome develops,Ovarian failure: may impair fertility in women,Congestive heart failure: increased incidence in patients receiving anthracyclines or with prior chest radiation
Concomitant use with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (e.g., alfuzosin, dihydroergotamine, ergotamine, methylergonovine, cisapride, pimozide, oral midazolam, triazolam, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension, or St. John's wort).,Concomitant use with drugs that strongly induce CYP3A (e.g., rifampin) due to risk of loss of virologic response.,Patients with severe hepatic impairment (Child-Pugh Class C).
Known hypersensitivity to bevacizumab or any components of the formulation,Recent hemoptysis (≥2.5 m L of red blood) within 21 days prior to treatment,Untreated central nervous system metastases (due to risk of bleeding; treat prior to bevacizumab)
Take with food to increase absorption. Avoid grapefruit juice as it may increase drug levels. No other specific food restrictions.
No specific food interactions known. No restrictions beyond general dietary advice for cancer patients.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant exposures. Second and third trimesters: No evidence of fetal harm; however, use only if clearly needed.
Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal impairment, and spontaneous abortion reported. Avoid use unless potential benefit justifies risk.
Unknown if excreted in human milk; M/P ratio not determined. Due to potential for HIV transmission and adverse effects, breastfeeding is not recommended.
No data on excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for at least 6 months after last dose.
No dose adjustment required for standard pregnancy. Pharmacokinetic changes (e.g., increased clearance) may occur, but clinical significance not established; standard dosing maintained.
No formal dose adjustment studies in pregnancy. Increased volume of distribution and clearance may occur, but no dose changes recommended. Use lowest effective dose with careful monitoring.
PREZCOBIX is a fixed-dose combination of darunavir (800 mg) and cobicistat (150 mg). Cobicistat is a potent CYP3A4 inhibitor; therefore, contraindicated with drugs highly dependent on CYP3A4 clearance. Darunavir requires boosting; cobicistat serves as pharmacoenhancer. No dose adjustment needed for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment. Monitor for hepatotoxicity, especially in patients with hepatitis B or C coinfection. Cobicistat increases serum creatinine by inhibiting tubular secretion, but does not affect renal function; e GFR decline typically 10-15 m L/min/1.73m2 within 2-4 weeks and then stabilizes. Do not use in patients requiring ritonavir-boosted darunavir if they are also on tenofovir disoproxil fumarate (more renal toxicity). Administer with food to enhance absorption.
Monitor blood pressure closely; hypertension is common. Hold therapy 28 days before elective surgery due to impaired wound healing. Use with caution in patients with cardiovascular disease or history of arterial thromboembolism. Proteinuria monitoring required; urine dipstick at baseline and regularly. Avoid in patients with recent hemoptysis or untreated CNS metastases.
Take PREZCOBIX with food, as food improves absorption.,Do not skip doses; missing doses can lead to drug resistance.,Inform your doctor of all other medications, including over-the-counter drugs, as serious interactions can occur.,Do not take with St. John's wort, certain seizure medications, or certain statins.,PREZCOBIX may increase creatinine levels in blood tests, but this does not mean your kidneys are damaged.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, pale stools, abdominal pain, nausea, vomiting.,Use effective contraception as this drug may reduce effectiveness of hormonal contraceptives (except progestin-only injections).
Report any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine/stool.,Inform your doctor immediately if you experience severe headache, vision changes, confusion, or seizures (signs of PRES).,Avoid surgery or dental procedures without notifying your oncologist; therapy may need to be paused.,Females of childbearing age must use effective contraception during and for 6 months after treatment.,Do not drive if you experience vision problems or dizziness from therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREZCOBIX vs AVASTIN, answered by our medical review team.
PREZCOBIX is a HIV Antiviral (Protease Inhibitor Combination) that works by PREZCOBIX is a fixed-dose combination of darunavir, a HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor. Darunavir selectively inhibits the cleavage of HIV-encoded Gag-Pol polyproteins in infected cells, preventing the formation of mature infectious virions. Cobicistat increases systemic exposure of darunavir by inhibiting CYP3A-mediated metabolism.. AVASTIN is a Antineoplastic (Angiogenesis Inhibitor) that works by Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREZCOBIX and AVASTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREZCOBIX is: Darunavir 800 mg (as two 400 mg tablets) plus cobicistat 150 mg (as one 150 mg tablet) orally once daily with food.. The standard adult dose of AVASTIN is: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREZCOBIX and AVASTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREZCOBIX is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant exposures. Second and third trimesters: No evidence of fetal harm; however, use on. AVASTIN is classified as Category C. Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal imp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.